Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia

Lancet

Volumn 352, Issue 9132, 1998, Pages 943-948

  Maclure, Malcolm ^a,b   Dormuth, Colin ^e   Naumann, Terryn ^c   McCormack, James ^d   Rangno, Robert ^d   Whiteside, Carl ^d   Wright, James M ^d  

^a MINISTRY OF HEALTH   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LIONS GATE HOSPITAL   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e University of British Columbia ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CANADA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 0032547571     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11390-3     Document Type: Article

References (31)

1. 1 Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG. Report of the Canadian hypertension society consensus conference: the pharmacologic treatment of essential hypertension. CMAJ 1993; 149: 575-84.
2. 2 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993; 153: 154-83.
3. 3 Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993; 307: 107-10.
4. 4 Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-87.
5. 5 WHO/ISH Guidelines subcommittee. Guidelines for the management of mild hypertension; memorandum from a WHO/ISH meeting. J Hypertens 1993; 11: 906-18.
6. 6 Insua JT, Sacks HS, Lau T, et al. Drug treatment of hypertension in the elderly: a meta analysis. Ann Intern Med 1994; 121: 355-62.
7. 7 Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104.
8. 8 Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405-12.
9. 9 Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. JAMA 1996; 275: 1577-80.
10. 10 Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E. Do results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE investigators. N Engl J Med 1992; 327: 241-47.
11. 11 Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA. Printed educational materials to improve the behaviour of health care professionals and patient outcomes (Cochrane Review). In: The Cochrane Library, issue 3, Oxford: Update Software, 1998.
12. 12 Thomson MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Audit and feedback to improve health professonal practice and health care outcomes (Parts 1 and 2, Cochrane Review). In: The Cochrane Library, issue 3, Oxford: Update Software, 1998.
13. 13 Thomson MA, Oxman AD, Davis DA, Haynes RB, Freemantle N, Harvey EL. Local opinion leaders to improve health professional practice and health care outcomes (Cochrane Review). In: The Cochrane Library, issue 3, Oxford: Update Software, 1998.
14. 14 Soumerai SB, Ross-Degnan D, Kahn JS. Effects of professional and media warnings about the association between aspirin use in children and Reye's Syndrome. Milbank Q 1992; 70: 155-82.
15. 15 Dean M. Risk reports push up pregnancies in Britain. Lancet 1996; 348: 951.
16. 16 Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. Circulation 1995; 91: 925.
17. 17 Psaty B, Heckbert S, Koepsell T, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-25.
18. 18 Reuter. Blood-pressure drugs feared bad for hearts. Vancouver Sun, March 11, 1995: A15.
19. 19 Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347: 1061-65.
20. 20 Furberg CD, Psaty M, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
21. 21 Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9: 1429.
22. 22 Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and risk of cancer in aged populations. Lancet 1996; 348: 493-97.
23. 23 Borhani N, Mercuri M, Borhani P, et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS): a randomized controlled trial. JAMA 1996; 276: 785-91.
24. 24 Therapeutics Initiative. Drugs of choice in the treatment of hypertension, part 1. Therapeutics Letter 7, June 1995.
25. 25 Therapeutics Initiative. Drugs of choice in the treatment of hypertension, part 2. Therapeutics Letter 8, July/August 1995.
26. 26 Health Protection Branch, Health Canada. Safety of calcium channel blockers in the treatment of patients with hypertension and coronary artery disease. Dear Doctor 1996; 44: 1-5.
27. 27 Rothman KJ. Modern epidemiology, 1st edn. Boston: Little Brown and Company, 1986: 173.
28. 28 Ault Barnett A. FDA committee rules calcium-channel blockers safe. Lancet 1996; 347: 313.
29. 29 Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275: 638.
30. 30 Myers MG. Drug may have caused huge number of deaths. CMAJ 1996; 155: 772-75.
31. 31 Oxman AD, Thomson MA, Davis DA, Haynes RB. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. CMAJ 1995; 153: 1423-31.